CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease including bone metastases with greater precision and resolution than current standard of care. With uncertainty in how to interpret PSA test results, especially for metastatic prostate cancer, this market is wide open for new and more specific diagnostic tests.
CTT’s PET agent is urgently needed to improve diagnosis and stratification of prostate cancer patients as it can be used to image both the location and extent of disease—something that all current urine and serum markers are unable to do. By affording more effective diagnosis and monitoring, imaging with CTT1057 will help inform personalized treatment choices and regimens to prevent or reduce pace of disease progression.
The Phase 1 clinical trial of CTT1057 PET in men with advanced prostate cancer was completed in August 2017. A summary of the findings can be found at the following address: https://radiology.ucsf.edu/blog/results-phase-i-ctt1057-human-clinical-trial-prostate-cancer-now-published. The journal article can be accessed at the following address: http://jnm.snmjournals.org/content/early/2018/11/20/jnumed.118.220715.long.
CTT licensed CTT1057 to Advanced Accelerator Applications(AAA)/Novartis in January 2018, who are continuing with the development and commercialization of CTT1057.
Distinguishing Features of CTT1057 Diagnostic
- PET imaging agent for prostate cancer with superior binding characteristics, excellent safety, cost of goods
- Recognizes a validated biomarker in a cancer with an unmet need
- Possibility for expansion into other cancers based on PSMA expression in the neovasculature
- Strong patent protection